Marksans Pharma Past Earnings Performance
Past criteria checks 5/6
Marksans Pharma has been growing earnings at an average annual rate of 21.2%, while the Pharmaceuticals industry saw earnings growing at 16.7% annually. Revenues have been growing at an average rate of 15.9% per year. Marksans Pharma's return on equity is 16%, and it has net margins of 14.7%.
Key information
21.2%
Earnings growth rate
19.3%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 15.9% |
Return on equity | 16.0% |
Net Margin | 14.7% |
Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Jul 28Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Jun 07Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
May 31Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
Feb 16Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
Jan 26We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Dec 02Marksans Pharma (NSE:MARKSANS) Seems To Use Debt Quite Sensibly
Jun 21Robust Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
Nov 17This Is The Reason Why We Think Marksans Pharma Limited's (NSE:MARKSANS) CEO Deserves A Bump Up To Their Compensation
Sep 16Marksans Pharma (NSE:MARKSANS) Is Increasing Its Dividend To ₹0.25
Sep 01Marksans Pharma (NSE:MARKSANS) Could Easily Take On More Debt
Jun 14Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
May 27Is Marksans Pharma (NSE:MARKSANS) A Risky Investment?
Feb 19Marksans Pharma Limited's (NSE:MARKSANS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 04Here's Why We Think Marksans Pharma (NSE:MARKSANS) Is Well Worth Watching
Jan 20Do Institutions Own Marksans Pharma Limited (NSE:MARKSANS) Shares?
Jan 05Shareholders Are Thrilled That The Marksans Pharma (NSE:MARKSANS) Share Price Increased 250%
Dec 21What Can We Conclude About Marksans Pharma's (NSE:MARKSANS) CEO Pay?
Dec 06These 4 Measures Indicate That Marksans Pharma (NSE:MARKSANS) Is Using Debt Safely
Nov 19Marksans Pharma Limited's (NSE:MARKSANS) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?
Nov 04If You Like EPS Growth Then Check Out Marksans Pharma (NSE:MARKSANS) Before It's Too Late
Oct 20Is Marksans Pharma Limited's (NSE:MARKSANS) Shareholder Ownership Skewed Towards Insiders?
Oct 05If You Had Bought Marksans Pharma (NSE:MARKSANS) Shares A Year Ago You'd Have Earned273% Returns
Sep 20A Look At The Fair Value Of Marksans Pharma Limited (NSE:MARKSANS)
Aug 20Revenue & Expenses Breakdown
How Marksans Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 24 | 22,680 | 3,338 | 3,059 | 0 |
31 Mar 24 | 21,774 | 3,137 | 2,936 | 0 |
31 Dec 23 | 21,034 | 3,164 | 2,875 | 0 |
30 Sep 23 | 19,971 | 2,965 | 2,752 | 0 |
30 Jun 23 | 19,184 | 2,743 | 2,637 | 0 |
31 Mar 23 | 18,521 | 2,653 | 2,521 | 0 |
31 Dec 22 | 17,842 | 2,123 | 2,436 | 0 |
30 Sep 22 | 16,670 | 2,004 | 2,375 | 0 |
30 Jun 22 | 15,756 | 1,847 | 2,326 | 0 |
31 Mar 22 | 14,908 | 1,868 | 2,250 | 0 |
31 Dec 21 | 14,069 | 2,367 | 2,351 | 0 |
30 Sep 21 | 14,026 | 2,473 | 2,269 | 0 |
30 Jun 21 | 14,064 | 2,518 | 2,037 | 0 |
31 Mar 21 | 13,762 | 2,385 | 2,096 | 0 |
31 Dec 20 | 13,817 | 2,018 | 1,908 | 0 |
30 Sep 20 | 13,142 | 1,724 | 1,833 | 0 |
30 Jun 20 | 12,203 | 1,476 | 1,700 | 0 |
31 Mar 20 | 11,344 | 1,208 | 1,785 | 0 |
31 Dec 19 | 10,463 | 879 | 1,719 | 0 |
30 Sep 19 | 9,972 | 834 | 1,677 | 0 |
30 Jun 19 | 10,099 | 780 | 1,631 | 0 |
31 Mar 19 | 10,001 | 804 | 1,659 | 0 |
31 Dec 18 | 9,523 | 666 | 1,601 | 0 |
30 Sep 18 | 9,223 | 582 | 1,599 | 0 |
30 Jun 18 | 9,272 | 463 | 1,474 | 0 |
31 Mar 18 | 9,127 | 358 | 1,534 | 0 |
31 Dec 17 | 8,918 | 343 | 1,528 | 0 |
30 Sep 17 | 8,949 | 275 | 1,550 | 0 |
30 Jun 17 | 8,015 | 187 | 1,492 | 0 |
31 Mar 17 | 7,672 | 113 | 1,547 | 0 |
31 Dec 16 | 7,926 | 70 | 1,475 | 0 |
30 Sep 16 | 7,948 | 136 | 1,458 | 0 |
30 Jun 16 | 8,699 | 481 | 1,424 | 0 |
31 Mar 16 | 8,933 | 785 | 1,270 | 0 |
31 Dec 15 | 8,536 | 1,093 | 1,585 | 0 |
30 Sep 15 | 8,495 | 1,191 | 1,397 | 0 |
30 Jun 15 | 8,045 | 1,154 | 728 | 0 |
31 Mar 15 | 7,967 | 1,094 | 758 | 0 |
31 Dec 14 | 7,850 | 950 | 1,482 | 0 |
30 Sep 14 | 7,405 | 897 | 1,121 | 0 |
30 Jun 14 | 6,914 | 786 | 693 | 0 |
31 Mar 14 | 6,300 | 719 | 1,091 | 0 |
31 Dec 13 | 5,950 | 1,020 | 1,013 | 0 |
30 Sep 13 | 5,406 | 877 | 994 | 0 |
Quality Earnings: MARKSANS has high quality earnings.
Growing Profit Margin: MARKSANS's current net profit margins (14.7%) are higher than last year (14.3%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MARKSANS's earnings have grown significantly by 21.2% per year over the past 5 years.
Accelerating Growth: MARKSANS's earnings growth over the past year (21.7%) exceeds its 5-year average (21.2% per year).
Earnings vs Industry: MARKSANS earnings growth over the past year (21.7%) exceeded the Pharmaceuticals industry 19.4%.
Return on Equity
High ROE: MARKSANS's Return on Equity (16%) is considered low.